Intravitreal methotrexate injection for intraocular lymphoma: a retrospective review
Keywords:
Central nervous system neoplasms, Intraocular lymphoma, Intravitreal injections, Methotrexate, UveitisAbstract
Objectives: To review the clinical outcomes of five patients with intraocular lymphoma (IOL) who were treated with intravitreal methotrexate (MTX) injections at the Hong Kong Eye Hospital after 2022.
Methods: We retrospectively reviewed medical records of five patients with definite or presumed IOL without systemic or central nervous system (CNS) involvement at the time of diagnosis, who were treated with intravitreal MTX injections.
Results: In total, eight eyes in one man and four women of Chinese ethnicity aged 54 to 90 (mean, 68.4) years underwent intravitreal MTX injections for IOL. Three patients had primary IOL; one patient had a relapse of diffuse large B-cell lymphoma with secondary IOL; and
one patient had a relapse of primary CNS lymphoma with ocular involvement. All five patients underwent diagnostic pars plana vitrectomy. Definitive cytology of malignant large B-cell lymphoma was achieved in only one eye, whereas four eyes were diagnosed
cytologically with a lymphoproliferative lesion. All patients received local intravitreal MTX injections with a mean of 20.9 injections given to each eye. All patients achieved ocular disease regression; however,
two patients with primary IOL eventually had CNS involvement.
Conclusion: Primary IOL carries a high risk of CNS disease progression. Local ocular treatments such as intravitreal MTX injections can effectively control the disease locally but do not prevent or treat CNS or systemic involvement. Monitoring by a multidisciplinary team using magnetic resonance imaging, positron emission tomography-computed tomography, and/or lumbar punctures can detect CNS or systemic disease early.
References
1. Tang LJ, Gu CL, Zhang P. Intraocular lymphoma. Int J Ophthalmol 2017;10:1301-7.
2. Buggage RR, Chan CC, Nussenblatt RB. Ocular manifestations of central nervous system lymphoma. Curr Opin Oncol 2001;13:137-42.
3. Levasseur SD, Wittenberg LA, White VA. Vitreoretinal lymphoma: a 20-year review of incidence, clinical and cytologic features, treatment, and outcomes. JAMA Ophthalmol 2013;131:50-5.
4. Plotkin SR, Batchelor TT. Primary nervous-system lymphoma. Lancet Oncol 2001;2:354-65.
5. Smith JR, Rosenbaum JT, Wilson DJ, et al. Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement. Ophthalmology 2002;109:1709-16.
6. Cho BJ, Yu HG. Risk factors for intraocular involvement in patients with primary central nervous system lymphoma. J Neurooncol 2014;120:523-9.
7. Cassoux N, Merle-Beral H, Leblond V, et al. Ocular and central nervous system lymphoma: clinical features and diagnosis. Ocul Immunol Inflamm 2000;8:243-50.
8. Berenbom A, Davila RM, Lin HS, Harbour JW. Treatment outcomes for primary intraocular lymphoma: implications for external beam radiotherapy. Eye (Lond) 2007;21:1198-201.
9. Qualman SJ, Mendelsohn G, Mann RB, Green WR. Intraocular lymphomas. Natural history based on a clinicopathologic study of eight cases and review of the literature. Cancer 1983;52:878-86.
10. Hoffman PM, McKelvie P, Hall AJ, Stawell RJ, Santamaria JD. Intraocular lymphoma: a series of 14 patients with clinicopathological features and treatment outcomes. Eye (Lond) 2003;17:513-21.
11. Peterson K, Gordon KB, Heinemann MH, DeAngelis LM. The clinical spectrum of ocular lymphoma. Cancer 1993;72:843-9.
12. Grimm SA, Pulido JS, Jahnke K, et al. Primary intraocular lymphoma: an International Primary Central Nervous System Lymphoma Collaborative Group Report. Ann Oncol 2007;18:1851-5.
13. Soussain C, Malaise D, Cassoux N. Primary vitreoretinal lymphoma: a diagnostic and management challenge. Blood 2021;138:1519-34.
14. Chan CC, Rubenstein JL, Coupland SE, et al. Primary vitreoretinal lymphoma: a report from an International Primary Central Nervous System Lymphoma Collaborative Group symposium. Oncologist 2011;16:1589-99.
15. Xu LT, Huang Y, Liao A, Anthony CL, Voloschin A, Yeh S. Multimodal diagnostic imaging in primary vitreoretinal lymphoma. Int J Retina Vitreous 2022;8:58.
16. Liu TY, Ibrahim M, Bittencourt M, Sepah YJ, Do DV, Nguyen QD. Retinal optical coherence tomography manifestations of intraocular lymphoma. J Ophthalmic Inflamm Infect 2012;2:215-8.
17. Zhao H, Wang X, Mao Y, Peng X. Longitudinal observation of OCT imaging is a valuable tool to monitor primary vitreoretinal lymphoma treated with intravitreal injections of methotrexate. BMC Ophthalmol 2020;20:10.
18. Ishida T, Ohno-Matsui K, Kaneko Y, et al. Fundus autofluorescence patterns in eyes with primary intraocular lymphoma. Retina 2010;30:23-32.
19. Tan WJ, Wang MM, Ricciardi-Castagnoli P, Chan ASY, Lim TS. Cytologic and molecular diagnostics for vitreoretinal lymphoma: current approaches and emerging single-cell analyses. Front Mol Biosci 2021;7:611017.
20. Akpek EK, Ahmed I, Hochberg FH, et al. Intraocular-central nervous system lymphoma: clinical features, diagnosis, and outcomes. Ophthalmology 1999;106:1805-10.
21. Davis JL, Miller DM, Ruiz P. Diagnostic testing of vitrectomy specimens. Am J Ophthalmol 2005;140:822-9.
22. Kimura K, Usui Y, Goto H; Japanese Intraocular Lymphoma Study Group. Clinical features and diagnostic significance of the intraocular fluid of 217 patients with intraocular lymphoma. Jpn J Ophthalmol 2012;56:383-9.
23. Frenkel S, Hendler K, Siegal T, Shalom E, Pe'er J. Intravitreal methotrexate for treating vitreoretinal lymphoma: 10 years of experience. Br J Ophthalmol 2008;92:383-8.
24. Zhou N, Xu X, Liu Y, Wang Y, Wei W. A proposed protocol of intravitreal injection of methotrexate for treatment of primary vitreoretinal lymphoma. Eye (Lond) 2022;36:1448-55.
25. Akiyama H, Takase H, Kubo F, et al. Systemic following intravitreal MTX administration prevents CNS infiltration of primary intraocular lymphoma. Blood 2014;124:3053.
26. de Smet MD. Management of non Hodgkin's intraocular lymphoma with intravitreal methotrexate. Bull Soc Belge Ophtalmol 2001;279:91-5.
27. Riemens A, Bromberg J, Touitou V, et al. Treatment strategies in primary vitreoretinal lymphoma: a 17-center European Collaborative Study. JAMA Ophthalmol 2015;133:191-7.
28. Dalvin LA, Pulido JS, Shields CL, et al. Vitreoretinal lymphoma: central nervous system lymphoma risk with unilateral or bilateral ocular tumour. A multicentre collaboration. Eye (Lond) 2023;37:54-61.
29. Akiyama H, Takase H, Kubo F, et al. High-dose methotrexate following intravitreal methotrexate administration in preventing central nervous system involvement of primary intraocular lymphoma. Cancer Sci 2016;107:1458-64.
30. Davis JL. Intraocular lymphoma: a clinical perspective. Eye (Lond) 2013;27:153-62.
31. Sagoo MS, Mehta H, Swampillai AJ, et al. Primary intraocular lymphoma. Surv Ophthalmol 2014;59:503-16.
32. Abrey LE, Batchelor TT, Ferreri AJ, et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 2005;23:5034-43.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Hong Kong Journal of Ophthalmology
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The Journal has a fully Open Access policy and publishes all articles under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) licence. For any use other than that permitted by this license, written permission must be obtained from the Journal.
